Literature DB >> 7936591

Treatment of oral candidiasis in HIV infection.

D Greenspan1.   

Abstract

Oral candidiasis is one of the most common clinical features of HIV infection. The lesion occurs in three predominant forms, and the two intraoral examples, pseudomembranous and erythematous, are equally predictive of the development of AIDS, independent of CD4 counts. The predominant species is C. albicans, although other species are occasionally found. Some studies claim correlation of salivary Candida counts with CD4 numbers or clinical stage of HIV-related disease, but this approach has not been used widely in HIV staging. Therapy with a variety of antifungal agents, including both topical and systemic drugs, is effective. New slow-release oral topical drug delivery systems may prove to be useful. Recently, examples of resistance to some drugs have been reported. Resistance may be associated with the emergence of different species.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936591     DOI: 10.1016/0030-4220(94)90149-x

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  8 in total

Review 1.  Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma.

Authors:  Peter A Reichart
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

2.  Susceptibilities of Candida albicans mouth isolates to antifungal agents, essentials oils and mouth rinses.

Authors:  Sara Carvalhinho; Ana Margarida Costa; Ana Cláudia Coelho; Eugénio Martins; Ana Sampaio
Journal:  Mycopathologia       Date:  2012-01-14       Impact factor: 2.574

3.  Azole-synergistic anti-candidal activity of altenusin, a biphenyl metabolite of the endophytic fungus Alternaria alternata isolated from Terminalia chebula Retz.

Authors:  Jatuporn Phaopongthai; Suthep Wiyakrutta; Duangdeun Meksuriyen; Nongluksna Sriubolmas; Khanit Suwanborirux
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

4.  HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2010-02-26

5.  HIV infection and microbial diversity in saliva.

Authors:  Yihong Li; Deepak Saxena; Zhou Chen; Gaoxia Liu; Willam R Abrams; Joan A Phelan; Robert G Norman; Gene S Fisch; Patricia M Corby; Floyd Dewhirst; Bruce J Paster; Alexis S Kokaras; Daniel Malamud
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

6.  Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants.

Authors:  Pranab K Mukherjee; Huichao Chen; Lauren L Patton; Scott Evans; Anthony Lee; Johnstone Kumwenda; James Hakim; Gaerolwe Masheto; Frederick Sawe; Mai T Pho; Kenneth A Freedberg; Caroline H Shiboski; Mahmoud A Ghannoum; Robert A Salata
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

7.  Human salivary histatin 5 fungicidal action does not induce programmed cell death pathways in Candida albicans.

Authors:  David Wunder; Jin Dong; Didi Baev; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  A study of antifungal drug sensitivity of Candida isolated from human immunodeficiency virus infected patients in Chennai, South India.

Authors:  Nadeem Jeddy; K Ranganathan; Uma Devi; Elizabeth Joshua
Journal:  J Oral Maxillofac Pathol       Date:  2011-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.